FDA.reportPublic FDA data

orforglipron 14.5 MG Oral Tablet [Foundayo]

RxCUI
2739866
RxNorm name
orforglipron 14.5 MG Oral Tablet [Foundayo]
Display name
orforglipron 14.5 MG Oral Tablet [Foundayo]
Full name
orforglipron 14.5 MG Oral Tablet [Foundayo]
Term type
SBD
Status
DailyMed mapping
Updated
2026-06-04 23:39:07

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
FOUNDAYOORFORGLIPRONEli Lilly and Company8ac446c5-feba-474f-a103-23facb9b5c622026-07-29Boxed warning, Warnings, Adverse reactionsExact identifier
rxcui: 2739866

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
8ac446c5-feba-474f-a103-23facb9b5c62Foundayo 14.5 MG Oral Tablet [PSN] · orforglipron 14.5 MG Oral Tablet [Foundayo] [SBD] · Foundayo 14.5 MG (equivalent to orforglipron calcium 14.81 MG) Oral Tablet [SY]35These highlights do not include all the information needed to use FOUNDAYO safely and effectively. See full prescribing information for FOUNDAYO. FOUNDAYO (orforglipron) tablets, for oral use Initial U.S. Approval: 202620260401